Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme
Related Experiment Video
Updated: Jun 18, 2026
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
Published on: November 11, 2016
Margarita Gutova1, Joseph Najbauer, Mike Y Chen
1Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010-3000, USA. mgutova@coh.org
Abstract:
Neural stem cells (NSCs) have been investigated in preclinical models as delivery vehicles for therapeutic genes for treatment of tumors in the central nervous system and other organs. Melanoma at early stages is effectively treated with surgery and radiotherapy, however metastatic disease is almost universally fatal, thus novel therapeutic approaches are needed. We studied the use of HB1.F3.CD therapeutic NSCs, a well-characterized clonal cell line derived from human fetal telencephalon, for their potential of secreting prodrug-activating enzyme. HB1.F3.CD cells were transduced by adenovirus encoding rabbit carboxylesterase (rCE), which converts CPT-11 into SN-38, a potent topoisomerase 1 inhibitor. In vitro cell migration assays revealed robust migration of NSCs to conditioned media from melanoma cells. Cytokine profiles showed that IL-6, IL-8, MCP-1 and TIMP-2, known chemoattractants for stem cells, were highly expressed by melanoma cells. Exposure of melanoma cells to conditioned media from the HB1.F3.CD.rCE cells in the presence of CPT-11 increased the tumor cell-killing effect by approximately 100-fold when compared to CPT-11 alone. Our data demonstrate the rational for NSC-based enzyme/prodrug therapeutic approach to target metastatic melanoma. Future experiments will evaluate the therapeutic efficacy of NSC-mediated melanoma therapy in animal models, which will provide the basis for targeted therapy in patients with advanced melanoma.
Insights
Neural stem cells (NSCs) engineered to deliver an enzyme showed significant potential in targeting metastatic melanoma. This approach converts a prodrug into a potent toxin, dramatically increasing tumor cell death.
Area of Science:
- Oncology
- Stem Cell Biology
- Gene Therapy
Background:
- Metastatic melanoma remains a significant challenge with limited treatment options.
- Neural stem cells (NSCs) are being explored as cellular delivery vehicles for cancer therapy.
- Developing novel therapeutic strategies for advanced melanoma is critical.
Purpose of the Study:
- To investigate the potential of genetically modified neural stem cells (NSCs) as a delivery system for treating metastatic melanoma.
- To evaluate the efficacy of HB1.F3.CD.rCE NSCs in converting a prodrug (CPT-11) to its active form (SN-38) for enhanced tumor cell killing.
Main Methods:
- Human fetal telencephalon-derived NSCs (HB1.F3.CD) were engineered to express rabbit carboxylesterase (rCE) via adenovirus transduction.
- In vitro migration assays assessed NSC chemotaxis towards melanoma cell-conditioned media.
- Melanoma cells were exposed to conditioned media from engineered NSCs and CPT-11 to evaluate tumor cell killing.
Main Results:
- Melanoma cells highly expressed chemoattractant cytokines (IL-6, IL-8, MCP-1, TIMP-2), promoting NSC migration.
- Exposure to HB1.F3.CD.rCE cells and CPT-11 resulted in a ~100-fold increase in melanoma cell death compared to CPT-11 alone.
- The study demonstrates the feasibility of an NSC-based enzyme/prodrug therapy for metastatic melanoma.
Conclusions:
- Genetically engineered NSCs can serve as effective delivery vehicles for enzyme/prodrug cancer therapy.
- This approach shows promise for targeting metastatic melanoma, warranting further investigation in preclinical models.
- NSC-mediated therapy offers a potential new avenue for treating advanced melanoma patients.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy